Home・Akciju saraksts・United Therapeutics Corp

United Therapeutics Corp

Slēgts

SektorsVeselības aprūpe

536.85 1.36

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

522.44

Max

540.58

Galvenie mērījumi
By Trading Economics
Ienākumi	-89M 275M
Pārdošana	-8.7M 782M
P/E Sektora vidējais	19.108 68.51
EPS	5.82
Peļņas marža	35.176
Darbinieki	1,400
EBITDA	-180M 344M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+22.93% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 28. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1B 26B
Iepriekšējā atvēršanas cena	535.49
Iepriekšējā slēgšanas cena	536.85

Ziņu noskaņojums

By Acuity

40%

60%

120 / 340 Rangs Healthcare

United Therapeutics Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. aug. 19:51 UTC

Social Media

News

United Therapeutics Corp shares are higher, driven by positive sentiment from significant insider transactions and strong investor interest amid a rising Biotechnology sector.

2026. g. 6. aug. 23:01 UTC

United Therapeutics Corp. shares are higher in after-market trading, continuing a steady increase since Thursday's close and remaining above the 20-day moving average.

2026. g. 5. aug. 20:02 UTC

News

Social Media

United Therapeutics reported second-quarter revenues of $783.3 million, missing estimates of $805.6 million, while EPS of $7.27 exceeded expectations by $0.18.

2026. g. 4. aug. 23:51 UTC

Shares of United Therapeutics Corp. are lower in after-market hours, remaining below the 20-day moving average and near the lower end of their one-month trading range.

2026. g. 3. aug. 19:16 UTC

Shares of United Therapeutics Corp are lower today, trading near the lower end of their one-month range amid a broader market rally in other sectors.

2026. g. 30. jūl. 14:36 UTC

Event

United Therapeutics shares are higher following the publication of full ADVANCE OUTCOMES study results in The Lancet, pending FDA approval for ralinepag.

2026. g. 29. jūl. 20:51 UTC

Event

United Therapeutics shares are higher in after-market trading following The Lancet's publication of results from the ADVANCE OUTCOMES study on Ralinepag for PAH.

2026. g. 28. jūl. 18:21 UTC

United Therapeutics Corp. shares are lower today, continuing a decline since Monday's close amid broader market trends and three consecutive sessions of lower finishes.

2026. g. 24. jūl. 16:36 UTC

News

Social Media

United Therapeutics appointed Victor Dzau to its Board of Directors, enhancing its strategic direction. Shares are modestly higher since Thursday's close.

2026. g. 22. jūl. 19:41 UTC

News

United Therapeutics filed an $833.4 million shelf registration for 1.5 million shares, contributing to downward pressure on shares amid broader market movements.

2026. g. 21. jūl. 16:56 UTC

United Therapeutics Corp is seeing modest gains today, with positive sentiment from Asian markets contributing to overall investor optimism. No specific news was identified.

Salīdzinājums

Cenas izmaiņa

United Therapeutics Corp Prognoze

Cenas mērķis

By TipRanks

22.93% augšup

Prognoze 12 mēnešiem

Vidējais 655.13 USD 22.93%

Augstākais 714 USD

Zemākais 515 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi United Therapeutics Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam United Therapeutics Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

120 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.